Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 650 across all filing types
Latest filing 2024-05-28 Major Shareholding Noti…
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) detailing a 'Correction Report' regarding a 'Stock Collateral Provision Agreement' involving the company's largest shareholder. It provides specific details on collateralized shares, loan amounts, and maturity dates. This type of disclosure regarding financing arrangements and collateralization of shares by major shareholders falls under the category of capital and financing updates.
2024-05-28 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) detailing a 'Correction Report' regarding a 'Stock Collateral Agreement' involving the company's largest shareholder. It provides specific details on collateralized shares, debt amounts, and the status of individual loan contracts. This type of disclosure is a standard regulatory filing in the Korean market (DART system) concerning capital structure and shareholder collateral, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A, Earnings, or Dividends.
2024-05-24 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding status, changes in ownership, and contractual relationships (such as pledges and loans) of the major shareholder and their special related parties. This falls under the category of Major Shareholding Notification.
2024-05-22 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) detailing a 'Correction Report' regarding a 'Stock Collateral Provision Agreement' involving a change in the largest shareholder. It provides specific details on collateralized shares, loan amounts, and creditor information. This type of disclosure regarding financing activities and capital structure changes falls under the 'Capital/Financing Update' category.
2024-05-16 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company 'GemVax&KAEL Co., Ltd.' covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial information, business operations, management discussions, and shareholding data, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-16 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a South Korean company (GemVax) detailing a 'Correction Report' regarding a 'Stock Collateral Provision Agreement' involving the company's largest shareholder. It provides specific details on collateralized shares, loan amounts, and maturity dates. This type of disclosure regarding capital structure and collateralization of shares by major shareholders is classified under 'Regulatory Filings' (RNS) as it is a specific corporate disclosure required by the exchange that does not fit into the other specialized categories like M&A, Dividends, or Earnings.
2024-05-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.